SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-18-017551
Filing Date
2018-09-27
Accepted
2018-09-27 16:01:42
Documents
7
Period of Report
2018-09-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20180925_8k.htm 8-K 30641
2 EXHIBIT 10.1 ex_124640.htm EX-10.1 120303
3 EXHIBIT 10.2 ex_124708.htm EX-10.2 31262
4 d2.jpg GRAPHIC 5591
5 d1.jpg GRAPHIC 6576
6 a2.jpg GRAPHIC 10006
7 a1.jpg GRAPHIC 11727
  Complete submission text file 0001437749-18-017551.txt   230848
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 181091024
SIC: 2834 Pharmaceutical Preparations